

ABSTRACT

Provided are uses for a substance capable of operating an aberrant gene product, which is prepared by a new drug creation technology that focuses on the cause of disease using information obtained from analysis of structural genes associated with diseases. Thus, the present invention includes (1) a pharmaceutical composition containing a substance capable of operating an aberrant gene product, (2) a method of using said substance for treatment of a disease caused by said product, (3) a screening method for said substance, and (4) a method of preparing a drug for treatment of a disease caused by said product.

09257650-022599

*not  
on separate  
page**B7*